Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CG | P48736 | 18/20 | 0.64 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.59 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.59 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.59 |
| ▸ | PRKDC | P78527 | 1/20 | 0.59 |
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 0.59 |
| ▸ | MAPT | P10636 | 2/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27963100 | 0.90 | PIK3CG (0.65) | PIK3CGPIK3CDPIK3CAPIK3CBPRKDC | |
| SCHEMBL189242 | 0.90 | PIK3CG (0.62) | PIK3CGPIK3CDPIK3CAPIK3CBPRKDC | |
| SCHEMBL189522 | 0.88 | PIK3CG (0.77) | PIK3CGPIK3CDPIK3CAPIK3CBPRKDC | |
| SCHEMBL188542 | 0.87 | PIK3CG (0.63) | PIK3CGPIK3CDPIK3CAPIK3CBPRKDC | |
| SCHEMBL188534 | 0.85 | PIK3CG (0.78) | PIK3CGPIK3CDPIK3CAPIK3CBPRKDC | |
| SCHEMBL188524 | 0.84 | PIK3CG (0.63) | PIK3CGPIK3CDPIK3CAPIK3CBPRKDC | |
| SCHEMBL189557 | 0.82 | PIK3CG (0.68) | PIK3CGPIK3CDPIK3CAPIK3CBPRKDC | |
| SCHEMBL22225673 | 0.81 | PIK3CG (0.61) | PIK3CGPIK3CDPIK3CAPIK3CBPRKDC | |
| SCHEMBL13452189 | 0.81 | PIK3CG (0.67) | PIK3CGPIK3CDPIK3CAPIK3CBPRKDC | |
| SCHEMBL1790874 | 0.81 | PIK3CG (0.61) | PIK3CGPIK3CDPIK3CAPIK3CBPRKDC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10328069-B2 | Phosphatidylinositol 3-kinase inhibitors for the treatment of lymphoproliferative malignancies | EXELIXIS, INC. (US) | 2019-06-25 | — | — | US | disclosed |
| US-20170296529-A1 | Phosphatidylinositol 3-Kinase Inhibitors for the Treatment of Lymphoproliferative Malignancies | EXELIXIS, INC. | 2017-10-19 | — | — | US | disclosed |
| US-20170296529-A1 | Phosphatidylinositol 3-Kinase Inhibitors for the Treatment of Lymphoproliferative Malignancies | EXELIXIS, INC. | 2017-10-19 | — | — | US | disclosed |
| US-9011863-B2 | Combinations of kinase inhibitors for the treatment of cancer | EXELIXIS, INC. (US) | 2015-04-21 | — | — | US | disclosed |
| US-8889664-B2 | Phosphatidylinositol 3-kinase inhibitors and methods of their use | EXELIXIS, INC. (US) | 2014-11-18 | — | — | US | disclosed |
| US-8889664-B2 | Phosphatidylinositol 3-kinase inhibitors and methods of their use | EXELIXIS, INC. (US) | 2014-11-18 | — | — | US | disclosed |
| US-20140303172-A1 | Phosphatidylinositol 3-Kinase Inhibitors for the Treatment of Lymphoproliferative Malignancies | EXELIXIS, INC. (US) | 2014-10-09 | — | — | US | disclosed |
| US-20140271665-A1 | Combinations of Kinase Inhibitors for the Treatment of Cancer | EXELIXIS, INC. (US) | 2014-09-18 | — | — | US | disclosed |
| EP-2139483-B9 | COMBINATION THERAPIES COMPRISING A QUINOXALINE INHIBITOR OF PI3K-ALPHA FOR USE IN THE TREATMENT OF CANCER | EXELIXIS INC (US) | 2014-05-21 | — | — | EP | disclosed |
| US-20140100215-A1 | Methods of Using PI3K and MEK Modulators | EXELIXIS, INC. (US) | 2014-04-10 | — | — | US | disclosed |
| US-7989622-B2 | Phosphatidylinositol 3-kinase inhibitors and methods of their use | EXELIXIS, INC. (US) | 2011-08-02 | — | — | US | disclosed |
| US-7989622-B2 | Phosphatidylinositol 3-kinase inhibitors and methods of their use | EXELIXIS, INC. (US) | 2011-08-02 | — | — | US | disclosed |
| US-20110123434-A1 | COMBINATION THERAPIES COMPRISING QUINOXALINE INHIBITORS OF P13K-ALPHA FOR USE IN THE TREATMENT OF CANCER | EXELIXIS, INC (US) | 2011-05-26 | — | — | US | disclosed |
| US-20110123434-A1 | COMBINATION THERAPIES COMPRISING QUINOXALINE INHIBITORS OF P13K-ALPHA FOR USE IN THE TREATMENT OF CANCER | EXELIXIS, INC (US) | 2011-05-26 | — | — | US | disclosed |
| US-20100087440-A1 | Phosphatidylinositol 3-Kinase Inhibitors and Methods of Their Use | EXELIXIS, INC. | 2010-04-08 | — | — | US | disclosed |
| US-20100087440-A1 | Phosphatidylinositol 3-Kinase Inhibitors and Methods of Their Use | EXELIXIS, INC. | 2010-04-08 | — | — | US | disclosed |
| US-20100087440-A1 | Phosphatidylinositol 3-Kinase Inhibitors and Methods of Their Use | EXELIXIS, INC. | 2010-04-08 | — | — | US | disclosed |
| US-20100075947-A1 | Methods of Using PI3K and MEK Modulators | EXELIXIS, INC. (US) | 2010-03-25 | — | — | US | disclosed |
| US-20100075947-A1 | Methods of Using PI3K and MEK Modulators | EXELIXIS, INC. (US) | 2010-03-25 | — | — | US | disclosed |
| US-20100075947-A1 | Methods of Using PI3K and MEK Modulators | EXELIXIS, INC. (US) | 2010-03-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140303172-A1 | Phosphatidylinositol 3-Kinase Inhibitors for the Treatment of Lymphoproliferative Malignancies | PIK3C2A, PIK3CA, PIK3C3 | PIK3CG 15/4885PIK3CD 14/4885PIK3CA 2/4885 |
| US-20100087440-A1 | Phosphatidylinositol 3-Kinase Inhibitors and Methods of Their Use | PIK3CA, PIK3CB, PIK3CG | PIK3CG 3/4885PIK3CD 4/4885PIK3CA 1/4885 |
| US-20100075947-A1 | Methods of Using PI3K and MEK Modulators | PIK3CA, PIK3CD, PIK3R1 | PIK3CG 5/4885PIK3CD 2/4885PIK3CA 1/4885 |
| US-20140100215-A1 | Methods of Using PI3K and MEK Modulators | PIK3CA, PIK3CD, PIK3R1 | PIK3CG 5/4885PIK3CD 2/4885PIK3CA 1/4885 |
| US-10328069-B2 | Phosphatidylinositol 3-kinase inhibitors for the treatment of lymphoproliferative malignancies | PIK3C2A, PIK3CA, PIK3C3 | PIK3CG 15/4885PIK3CD 14/4885PIK3CA 2/4885 |
| US-20110123434-A1 | COMBINATION THERAPIES COMPRISING QUINOXALINE INHIBITORS OF P13K-ALPHA FOR USE IN THE TREATMENT OF CANCER | TP53, PHKG1, TNNI3K | PIK3CG 370/4885PIK3CD 339/4885PIK3CA 145/4885 |
| US-20140271665-A1 | Combinations of Kinase Inhibitors for the Treatment of Cancer | ERBB2, EGFR, ERBB3 | PIK3CG 328/4885PIK3CD 298/4885PIK3CA 79/4885 |
| US-20170296529-A1 | Phosphatidylinositol 3-Kinase Inhibitors for the Treatment of Lymphoproliferative Malignancies | PIK3C2A, PIK3CA, PIK3C3 | PIK3CG 15/4885PIK3CD 14/4885PIK3CA 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.